abugarciablackmax3castingreel| Kangtai Biotech: The application for clinical trials of a new population aged 6-35 months for tetravalent influenza virus split vaccine was accepted

Securities Times e Company Newsabugarciablackmax3castingreel, Kangtai Biotech (300601) announced on the evening of May 20abugarciablackmax3castingreelThe company recently received an acceptance notice issued by the State Food and Drug Administration, agreeing to accept clinical trial applications for new people aged 6-35 months for the tetravalent influenza virus split vaccine developed by the company. The company's tetravalent influenza virus split vaccine (people aged 3 and above) is currently in Phase I and III clinical trials. This time, the company's tetravalent influenza virus split vaccine clinical trial application for a new population aged 6-35 months has been accepted.